Metastatic colorectal cancer patients amenable for anti-EGFR mAb treatment currently receive relatively high doses (250–500 mg/m2 of cetuximab or 6 mg/kg of panitumumab), which is aimed to block EGF binding to EGFR. Here, EGFR is linked to colorectal cancer.